Delving into the Latest Updates on Jilin Jinsheng Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Cardiovascular Diseases

Other Diseases

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Enzyme	1

Top 5 Target	Count

Fibrinogen x Plasminogen activators	1

主要目的：证实吉林惠升生物制药有限公司研制的德谷胰岛素注射液在2型糖尿病受试者中的疗效非劣于诺和诺德生产的德谷胰岛素注射液（商品名：诺和达®）。次要目的：评价吉林惠升生物制药有限公司研制的德谷胰岛素注射液在2型糖尿病受试者中的安全性。

[Translation]

Primary objective: To confirm that the efficacy of degludec insulin injection developed by Jilin Huisheng Biopharmaceutical Co., Ltd. in subjects with type 2 diabetes is non-inferior to that of degludec insulin injection (trade name: Tresiba®) produced by Novo Nordisk. Secondary objective: To evaluate the safety of degludec insulin injection developed by Jilin Huisheng Biopharmaceutical Co., Ltd. in subjects with type 2 diabetes.

Start Date28 Nov 2020

Sponsor / Collaborator

Jilin Jinsheng Pharmaceutical Co. Ltd.

[+1]

CTR20192122 / RecruitingPhase 1

评价德谷胰岛素注射液与诺和达在中国健康受试者中的PK/PD及安全性随机、开放、单剂量、两周期、交叉临床研究

[Translation] A randomized, open-label, single-dose, two-period, crossover clinical study to evaluate the PK/PD and safety of degludec insulin injection and Tresiba in healthy Chinese subjects

评估在中国健康成年受试者中单剂量皮下注射吉林津升制药有限公司研制的德谷胰岛素注射液与诺和达®/TRESIBA®相比的药代动力学 (PK) 特征。

[Translation]

To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous dose of insulin degludec injection developed by Jilin Jinsheng Pharmaceutical Co., Ltd. compared with Tresiba®/TRESIBA® in healthy adult Chinese subjects.

Start Date11 Dec 2019

Sponsor / Collaborator

Jilin Jinsheng Pharmaceutical Co. Ltd.

[+1]

CTR20190161 / CompletedPhase 1

门冬胰岛素注射液在中国健康受试者中的随机、开放、单剂量、2制剂、2周期、2序列、双交叉生物等效性试验研究

[Translation] A randomized, open-label, single-dose, two-formulation, two-cycle, two-sequence, double-crossover bioequivalence study of insulin aspart injection in Chinese healthy subjects

主要目的：采用正葡萄糖钳夹技术，在健康男性受试者中比较吉林津升制药有限公司研制的门冬胰岛素注射液与诺和锐®单剂量皮下注射药代动力学的生物等效性；次要目的：评价门冬胰岛素注射液在健康受试者中的安全性。

[Translation]

Primary objective: To compare the bioequivalence of the pharmacokinetics of single-dose subcutaneous injection of insulin aspart injection developed by Jilin Jinsheng Pharmaceutical Co., Ltd. and NovoRapid® in healthy male subjects using the euglycemic clamp technique; Secondary objective: To evaluate the safety of insulin aspart injection in healthy subjects.

Start Date14 Jun 2019

Sponsor / Collaborator

Jilin Jinsheng Pharmaceutical Co. Ltd.

100 Clinical Results associated with Jilin Jinsheng Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Jilin Jinsheng Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Jilin Jinsheng Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Jilin Jinsheng Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Plasmin ( Fibrinogen x Plasminogen activators )	Thromboangiitis Obliterans More	Approved
Insulin aspart (Huisheng Biological) ( INSR )	Diabetes Mellitus, Type 2 More	Pending